Displaying all 2 publications

Abstract:
Sort:
  1. Fulltext Effectiveness of a pharmacist-led tele-psychiatric clinic in managing drug-related problems
    Al Shakhori M, Arain S, Abdulsalim S, Salim Karattuthodi M, Al Dhamen M, Almutairi S, et al.
    J Pharm Policy Pract, 2025;18(1):2460038.
    PMID: 39931673 DOI: 10.1080/20523211.2025.2460038
    BACKGROUND: The study aimed to evaluate the effectiveness of telepsychiatry combined with the expertise of psychiatric clinical pharmacists in identifying and addressing drug-related problems (DRPs) associated with psychotropic medications. Additionally, the research assessed physicians' acceptance of pharmacists' recommendations for managing these DRPs.

    METHODS: A cohort retrospective study was conducted at a leading tertiary care hospital in Saudi Arabia spanning from January 2023 to January 2024 in a psychiatry setting. The study comprehensively examined all instances of interventions for DRPs facilitated through patient-initiated telepsychiatry encounters with psychiatric clinical pharmacists. Detailed and meticulously recorded notes from patient chart reviews, documented by the pharmacist in the Electronic Health Record (EHR), during each encounter, were reviewed. These notes provided significant information on psychiatric diagnosis, identified DRPs and the specific interventions and recommendations proposed by the clinical pharmacist to the attending physician. The Krska classification was utilised to classify and analyse the identified DRPs, ensuring a structured and systematic approach to the study's findings.

    RESULTS: A total of 259 pharmacist interventions were made, and the results revealed a remarkably high acceptance rate of 98.5% among physicians. The most common intervention (16.21%) involved targeted education to improve medication adherence. Additionally, substantial efforts were directed towards rectifying inappropriate dosage regimens, accounting for 13.51% of DRPs resolved by the pharmacist. Noteworthy interventions also encompassed the identification and management of potential or suspected adverse reactions, comprising 12.35% of the interventions, along with interventions addressing concerns regarding potentially ineffective therapy, which constituted 11.59%.

    CONCLUSION: The study underscores the critical role of pharmacists in psychiatric care, with high physician acceptance of their interventions. The diverse range of DRPs highlights the need to expand clinical pharmacy services and integrate pharmacists into psychiatric teams. Our findings clearly demonstrate that integrating pharmacists into psychiatric care settings is beneficial. This approach enhances DRP identification and management, ultimately enhancing patient care and treatment outcomes.

  2. Fulltext Harnessing chia seed polysaccharides for green synthesis of copper-based nanoparticles with antidiabetic and anti-inflammatory activities
    Khan F, Jamil Y, Wajid R, Khan A, Yaseen M, Law D, et al.
    PLoS One, 2026;21(10):e0361692.
    PMID: 42961858 DOI: 10.1371/journal.pone.0361692
    Diabetes mellitus and chronic inflammation are global health issues, exacerbated by the incomplete control of metabolic-inflammatory pathways and the adverse effects of long-term pharmacotherapy. The development of multifunctional therapeutic nanomaterials via green nanotechnology has recently garnered attention. In this study, we synthesized copper-based nanoparticles (Cu NPs) using Salvia hispanica (chia) seed-derived polysaccharides and characterized their in vitro anti-inflammatory and antidiabetic activities, as well as in vivo antidiabetic effects in an alloxan-induced diabetic mouse model. Successful formation of polysaccharide-based Cu NPs was confirmed using UV-Visible, FTIR, XRD, and SEM analyses. Hemocompatibility assessment showed concentration-dependent hemolysis by Cu NPs (0.92 ± 0.06%, 5.71 ± 0.44%, and 8.42 ± 0.63% at the respective tested concentrations), indicating reduced hemocompatibility at higher concentrations. In the HRBC membrane stabilization assay, Cu NPs exhibited dose-dependent inhibition of hemolysis (45.83 ± 1.7% to 70.59 ± 2.1%), while heat hemolysis was reduced by 72.91 ± 1.5% at 1000 µg/mL. Enzyme inhibition studies showed significant inhibition of α-amylase (58.45 ± 0.7% to 87.20 ± 2.1%) and α-glucosidase (83.87 ± 1.6% at 1000 µg/mL) compared to acarbose. Glucose uptake in yeast cells increased to 59.87 ± 0.3% at 1000 µg/mL. In alloxan-induced diabetic mice, Cu NPs (150 mg/kg) reduced fasting blood glucose from 287 ± 4.2 to 131 ± 7.02 mg/dL over 30 days and improved lipid profiles (e.g., decreased total cholesterol to 85 ± 1.3 mg/dL and increased HDL to 39.8 ± 1.2 mg/dL). Histopathological analyses showed restoration of pancreatic and hepatic architecture. Collectively, chia seed polysaccharide-mediated copper-based nanoparticles exhibited anti-hyperglycemic, anti-inflammatory, and lipid-modulating activities under the investigated experimental conditions, supporting their further evaluation for diabetes-related applications.
Related Terms
    Try searching for something
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links